MCID: NRL004
MIFTS: 52

Neuroleptic Malignant Syndrome

Categories: Blood diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuroleptic Malignant Syndrome

MalaCards integrated aliases for Neuroleptic Malignant Syndrome:

Name: Neuroleptic Malignant Syndrome 12 77 54 55 60 38 56 45 15 17 74

Characteristics:

Orphanet epidemiological data:

60
neuroleptic malignant syndrome
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 60  
Rare neurological diseases


Summaries for Neuroleptic Malignant Syndrome

NIH Rare Diseases : 54 Neuroleptic malignant syndrome is a rare neurological condition that is caused by an adverse reaction to neuroleptic (tranquilizer) or antipsychotic drugs. These drugs are commonly prescribed for the treatment of schizophrenia and other neurological, mental, or emotional disorders. Affected people may experience high fever, muscle stiffness, sweating, unstable blood pressure, altered mental status, and autonomic dysfunction. In most cases, the condition develops within the first 2 weeks of treatment with the drug; however, it may develop any time during the therapy period. The exact underlying cause of neuroleptic malignant syndrome is unknown. In some cases, more than one family member can be affected which suggests there may be a genetic component. Upon diagnosis of the condition, the neuroleptic or antipsychotic drug is generally discontinued under a physician's supervision. Medications and/or other interventions may also be recommended to manage symptoms.

MalaCards based summary : Neuroleptic Malignant Syndrome is related to serotonin syndrome and malignant hyperthermia. An important gene associated with Neuroleptic Malignant Syndrome is PIK3C2A (Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha). The drugs Artemether and Lumefantrine have been mentioned in the context of this disorder. Affiliated tissues include kidney, brain and bone, and related phenotypes are hyperhidrosis and fever

Disease Ontology : 12 A nervous system disease that is characterized by hyperthermia, muscular rigidity, autonomic dysfunction and altered consciousness and is associated with administration of antipsychotic and other central dopaminergic blockers.

NINDS : 55 Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction. In most cases, the disorder develops within the first 2 weeks of treatment with the drug; however, the disorder may develop any time during the therapy period. The syndrome can also occur in people taking anti-Parkinsonism drugs known as dopaminergics if those drugs are discontinued abruptly.

Wikipedia : 77 Neuroleptic malignant syndrome (NMS) is a life-threatening reaction that can occur in response to... more...

Related Diseases for Neuroleptic Malignant Syndrome

Diseases related to Neuroleptic Malignant Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
# Related Disease Score Top Affiliating Genes
1 serotonin syndrome 30.8 CYP2D6 HTR1A
2 malignant hyperthermia 30.7 MB PIK3C2A RYR1
3 tardive dyskinesia 30.3 CYP2D6 DRD2
4 disseminated intravascular coagulation 30.2 MB PIK3C2A
5 myoglobinuria 30.2 MB PIK3C2A
6 galactorrhea 30.1 CYP2D6 DRD2
7 plexopathy 30.0 MB PIK3C2A
8 muscle disorders 30.0 PIK3C2A RYR1
9 generalized anxiety disorder 29.6 DRD2 HTR1A
10 acute myocardial infarction 29.6 CHKB MB PIK3C2A
11 compartment syndrome 29.4 CHKB MB PIK3C2A
12 parkinson disease, late-onset 29.3 CYP2D6 DRD2 HTR1A
13 encephalitis 10.4
14 schizophrenia 10.3
15 dementia 10.3
16 virus associated hemophagocytic syndrome 10.2 MB PIK3C2A
17 delusional disorder 10.2 CYP2D6 DRD2
18 interstitial myocarditis 10.2 MB PIK3C2A
19 ocular motor apraxia 10.2
20 posterior myocardial infarction 10.2 MB PIK3C2A
21 myositis fibrosa 10.2 MB PIK3C2A
22 gas gangrene 10.2 MB PIK3C2A
23 anuria 10.2 MB PIK3C2A
24 dystonia 10.2
25 intermediate coronary syndrome 10.2 MB PIK3C2A
26 pseudohyperkalemia, familial, 2, due to red cell leak 10.2 MB PIK3C2A
27 acute mountain sickness 10.2 MB PIK3C2A
28 gastroparesis 10.2 CYP2D6 DRD2
29 huntington disease 10.1
30 myocardial infarction 10.1
31 brain injury 10.1
32 status epilepticus 10.1
33 encephalopathy 10.1
34 acute kidney failure 10.1 MB PIK3C2A
35 substance-induced psychosis 10.1 DRD2 HTR1A
36 social phobia 10.1 DRD2 HTR1A
37 periodic limb movement disorder 10.1 DRD2 HTR1A
38 multiple sclerosis 10.1
39 autism 10.1
40 rigidity and multifocal seizure syndrome, lethal neonatal 10.1
41 bipolar disorder 10.1
42 cerebral palsy 10.1
43 thrombocytopenia 10.1
44 traumatic brain injury 10.1
45 acquired immunodeficiency syndrome 10.1
46 cocaine abuse 10.1
47 subacute delirium 10.1
48 neuropathy 10.1
49 cerebellar degeneration 10.1
50 myoclonus 10.1

Graphical network of the top 20 diseases related to Neuroleptic Malignant Syndrome:



Diseases related to Neuroleptic Malignant Syndrome

Symptoms & Phenotypes for Neuroleptic Malignant Syndrome

Human phenotypes related to Neuroleptic Malignant Syndrome:

60 33 (show top 50) (show all 56)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000975
2 fever 60 33 hallmark (90%) Very frequent (99-80%) HP:0001945
3 extrapyramidal muscular rigidity 60 33 hallmark (90%) Very frequent (99-80%) HP:0007076
4 mutism 60 33 hallmark (90%) Very frequent (99-80%) HP:0002300
5 abnormal autonomic nervous system physiology 60 33 hallmark (90%) Very frequent (99-80%) HP:0012332
6 tremor 60 33 frequent (33%) Frequent (79-30%) HP:0001337
7 dysphagia 60 33 frequent (33%) Frequent (79-30%) HP:0002015
8 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
9 leukocytosis 60 33 frequent (33%) Frequent (79-30%) HP:0001974
10 metabolic acidosis 60 33 frequent (33%) Frequent (79-30%) HP:0001942
11 tachycardia 60 33 frequent (33%) Frequent (79-30%) HP:0001649
12 drooling 60 33 frequent (33%) Frequent (79-30%) HP:0002307
13 elevated serum creatine kinase 33 frequent (33%) HP:0003236
14 muscle spasm 33 frequent (33%) HP:0003394
15 chorea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002072
16 hypotension 60 33 occasional (7.5%) Occasional (29-5%) HP:0002615
17 proteinuria 60 33 occasional (7.5%) Occasional (29-5%) HP:0000093
18 dehydration 60 33 occasional (7.5%) Occasional (29-5%) HP:0001944
19 vomiting 60 33 occasional (7.5%) Occasional (29-5%) HP:0002013
20 hyperuricemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002149
21 pulmonary embolism 60 33 occasional (7.5%) Occasional (29-5%) HP:0002204
22 anxiety 60 33 occasional (7.5%) Occasional (29-5%) HP:0000739
23 elevated hepatic transaminase 60 33 occasional (7.5%) Occasional (29-5%) HP:0002910
24 agitation 60 33 occasional (7.5%) Occasional (29-5%) HP:0000713
25 nasogastric tube feeding 60 33 occasional (7.5%) Occasional (29-5%) HP:0040288
26 coma 60 33 occasional (7.5%) Occasional (29-5%) HP:0001259
27 hypocalcemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002901
28 hypertensive crisis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100735
29 thrombocytosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001894
30 increased lactate dehydrogenase activity 60 33 occasional (7.5%) Occasional (29-5%) HP:0025435
31 hyponatremia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002902
32 acute kidney injury 60 33 occasional (7.5%) Occasional (29-5%) HP:0001919
33 encephalopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0001298
34 urinary incontinence 60 33 occasional (7.5%) Occasional (29-5%) HP:0000020
35 hyperkalemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002153
36 nausea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002018
37 hyperphosphatemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002905
38 myoglobinuria 60 33 occasional (7.5%) Occasional (29-5%) HP:0002913
39 rhabdomyolysis 60 33 occasional (7.5%) Occasional (29-5%) HP:0003201
40 oculogyric crisis 60 33 occasional (7.5%) Occasional (29-5%) HP:0010553
41 elevated alkaline phosphatase 60 33 occasional (7.5%) Occasional (29-5%) HP:0003155
42 hypomagnesemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002917
43 rigors 60 33 occasional (7.5%) Occasional (29-5%) HP:0025145
44 delirium 60 33 occasional (7.5%) Occasional (29-5%) HP:0031258
45 hypernatremia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003228
46 aspiration pneumonia 60 33 occasional (7.5%) Occasional (29-5%) HP:0011951
47 hypothermia 60 33 very rare (1%) Very rare (<4-1%) HP:0002045
48 thrombocytopenia 60 33 very rare (1%) Very rare (<4-1%) HP:0001873
49 sepsis 60 33 very rare (1%) Very rare (<4-1%) HP:0100806
50 bradycardia 60 33 very rare (1%) Very rare (<4-1%) HP:0001662

MGI Mouse Phenotypes related to Neuroleptic Malignant Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.55 CHKB DRD2 HTR1A NHLRC1 RYR1
2 homeostasis/metabolism MP:0005376 9.5 CHKB DRD2 HTR1A MB NHLRC1 PIK3C2A
3 muscle MP:0005369 9.02 CHKB DRD2 MB NHLRC1 RYR1

Drugs & Therapeutics for Neuroleptic Malignant Syndrome

Drugs for Neuroleptic Malignant Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Artemether Approved Phase 4 71963-77-4 68911 119380
2
Lumefantrine Approved Phase 4 82186-77-4 6437380
3
Dopamine Approved Phase 4,Phase 3,Phase 2 62-31-7, 51-61-6 681
4
Haloperidol Approved Phase 4,Phase 3,Phase 2 52-86-8 3559
5
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
6 Antipsychotic Agents Phase 4,Phase 3,Phase 2
7 Antiparasitic Agents Phase 4
8 Artemether, Lumefantrine Drug Combination Phase 4
9 Antiprotozoal Agents Phase 4
10 Anti-Infective Agents Phase 4
11 Antimalarials Phase 4
12 Dopamine Antagonists Phase 4,Phase 3,Phase 2
13 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Haloperidol decanoate Phase 4,Phase 3,Phase 2
15 Tranquilizing Agents Phase 4,Phase 3,Phase 2
16 Antiemetics Phase 4,Phase 3,Phase 2
17 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
20 Dopamine Agents Phase 4,Phase 3,Phase 2
21 Psychotropic Drugs Phase 4,Phase 3,Phase 2
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Cholinergic Agents Phase 4,Not Applicable
24 Central Nervous System Stimulants Phase 4,Not Applicable
25 Solifenacin succinate Phase 4 242478-38-2
26 Muscarinic Antagonists Phase 4
27 Cholinergic Antagonists Phase 4
28 Dopamine Uptake Inhibitors Phase 4
29 Neurotransmitter Uptake Inhibitors Phase 4
30
Dronabinol Approved, Illicit Phase 3,Phase 2 1972-08-3 16078
31
Nabilone Approved, Investigational Phase 3,Phase 2 51022-71-0 5284592
32
Carbidopa Approved Phase 3 28860-95-9 34359
33
Levodopa Approved Phase 3 59-92-7 6047
34
Ziprasidone Approved Phase 3 146939-27-7 60854
35 Hormones Phase 3,Phase 2
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
37 Hormone Antagonists Phase 3,Phase 2
38 Quetiapine Fumarate Phase 3 111974-72-2
39 Antidepressive Agents Phase 3
40 Immunologic Factors Phase 3,Phase 1
41 Dopamine agonists Phase 3
42 Anti-Anxiety Agents Phase 3,Phase 2
43 Analgesics Phase 3,Phase 2,Not Applicable
44 Analgesics, Non-Narcotic Phase 3,Phase 2
45 Hallucinogens Phase 3,Phase 2
46 Cannabinoid Receptor Agonists Phase 3,Phase 2
47 Aromatic Amino Acid Decarboxylase Inhibitors Phase 3
48 Carbidopa, levodopa drug combination Phase 3
49 Adjuvants, Immunologic Phase 3
50 Antiparkinson Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Impact of Enhanced Health Facility Care in Uganda Completed NCT01024426 Phase 4
2 Agents Intervening Against Delirium in Intensive Care Unit Recruiting NCT03392376 Phase 4 Haloperidol Injection
3 Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome Active, not recruiting NCT03468465 Phase 4 Solifenacin Succinate
4 The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease. Terminated NCT01244269 Phase 4 Methylphenidate;Methylphenidate;Placebo 10;Placebo 20
5 Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium Completed NCT01811459 Phase 3 Quetiapine;Haloperidol;Placebo
6 Nabilone for Non-motor Symptoms in Parkinson's Disease Recruiting NCT03773796 Phase 3 Nabilone 0.25 mg
7 A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) Recruiting NCT02549092 Phase 3 ABT-SLV187
8 The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study Active, not recruiting NCT01211522 Phase 3 Haloperidol;Ziprasidone;Placebo
9 Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study Unknown status NCT01174810 Phase 2 Exenatide
10 Mindfulness Based Intervention (MBI) on the Quality of Life and Non-Motor Symptoms (NMS) of Persons With PD Completed NCT01607697 Phase 2
11 Neuromuscular Magnetic Stimulation in ALS Patients Completed NCT03618966 Phase 2
12 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia Completed NCT01176721 Phase 2
13 Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's. Completed NCT01701544 Phase 1, Phase 2
14 Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML Recruiting NCT03922100 Phase 1, Phase 2 NMS-03592088
15 Nabilone for Non-motor Symptoms in Parkinson's Disease Recruiting NCT03769896 Phase 2 Nabilone 0.25 mg;Placebo
16 Rapid Agitation Control With Ketamine in the Emergency Department Recruiting NCT03375671 Phase 2 Ketalar;Midazolam injection;Haloperidol
17 Identification of a Biomarker Predictive of Evolution of Parkinson Disease Recruiting NCT03230526 Phase 2 [18F]DPA-714 PET scan
18 Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture. Recruiting NCT03545347 Phase 2 Nandrolone Decanoate;Sodium Chloride 9mg/ml Injection
19 A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease Recruiting NCT03582137 Phase 2 Cannabidiol
20 Recovery of Physical Functioning After Hip Fracture Unknown status NCT02780076 Phase 1
21 Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors Completed NCT01014429 Phase 1 NMS-1286937
22 Safety of RG2077 in Patients With Multiple Sclerosis Completed NCT00076934 Phase 1 RG2077 (CTLA4-IgG4m)
23 Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity Completed NCT02216188 Phase 1
24 Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA) Completed NCT02618941 Phase 1
25 Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients Active, not recruiting NCT02854683 Phase 1 Normal Saline
26 Study of the Fecal Microbiome in Patients With Parkinson's Disease Not yet recruiting NCT03671785 Phase 1 PRIM-DJ2727;Placebo oral capsule
27 Study of NMS-1116354 in Solid Tumors Terminated NCT01016327 Phase 1 NMS-1116354
28 Study of NMS-1116354 in Advanced/Metastatic Solid Tumors Terminated NCT01092052 Phase 1 NMS-1116354
29 Occipital Nerve Stimulation in the Treatment of Migraine Terminated NCT01855672 Phase 1
30 Neuromuscular Electrostimulation in Radiocephalic Fistula Unknown status NCT02925845 Not Applicable
31 The Iliac Arterio-venous Fistula for Treatment of Neurally Mediated Syncope Study Unknown status NCT02388087 Not Applicable
32 Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients Unknown status NCT01022450
33 Activity Dependent Rehabilitation Model to Improve Bone and Muscle Outcomes Unknown status NCT02309983 Not Applicable
34 Understanding and Appraising the New Medicine Service in England Completed NCT01635361 Not Applicable
35 Incidence of Residual Neuromuscular Blockade in Intra-abdominal Surgery: A Prospective, Observational Study Completed NCT02984839
36 Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine Completed NCT01504529
37 The Effect of Parkinson Kinetigraph Recordings on the Management and Outcome in Parkinson's Disease Completed NCT03152721 Not Applicable
38 Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307) Completed NCT01495741
39 Help-seeking for Health Problems in People With Parkinson's Completed NCT03275649
40 A Feasibility Study of the Impact on Blood Pressure Control of Supplementing Community Pharmacist Services With Structured Information on Blood Pressure and Its Treatment Completed NCT01939860 Not Applicable
41 Distribution of Non-Motor Symptoms in Idiopathic Parkinson's Disease and Secondary Parkinsonism Completed NCT03432338
42 Incidence of Postoperative Neuromuscular Blockade in Post-Anesthesia Care Unit at Parkland Hospital: Does Size Matter? Completed NCT03111082
43 Long Time Follow up After HJ Following Iatrogenic Bile Duct Injuries Completed NCT01447030
44 Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks. Completed NCT01702259 Not Applicable
45 Postoperative Blood Transfusion for Frail Elderly With Hip Fracture Completed NCT01102010 Early Phase 1
46 rTMS Effects on Smoking Cessation and Cognition in Schizophrenia Completed NCT00736710 Not Applicable
47 Effects of Green Light Therapy on Body Contouring and Cellulite Completed NCT03647748 Not Applicable
48 Functional Performance Following Emergency High-risk Abdominal Surgery Completed NCT02124356
49 Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults Completed NCT03761979 Not Applicable
50 Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy Completed NCT02734485 Not Applicable

Search NIH Clinical Center for Neuroleptic Malignant Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: neuroleptic malignant syndrome

Genetic Tests for Neuroleptic Malignant Syndrome

Anatomical Context for Neuroleptic Malignant Syndrome

MalaCards organs/tissues related to Neuroleptic Malignant Syndrome:

42
Kidney, Brain, Bone, Testes, Tongue, Thyroid, Hypothalamus

Publications for Neuroleptic Malignant Syndrome

Articles related to Neuroleptic Malignant Syndrome:

(show top 50) (show all 1475)
# Title Authors Year
1
Electroconvulsive therapy for catatonia secondary to neuroleptic malignant syndrome in a patient with multiple sclerosis. ( 31072113 )
2019
2
Anti-N-methyl-D-aspartate receptor encephalitis mimics neuroleptic malignant syndrome: case report and literature review. ( 31040676 )
2019
3
Lifesaving Electroconvulsive Therapy for a Child With Autism Spectrum Disorder, Severe Self-Injurious Behavior, and Neuroleptic Malignant Syndrome. ( 31022044 )
2019
4
Aripiprazole Induced Late Neuroleptic Malignant Syndrome. ( 30730330 )
2019
5
Emergent Treatment of Neuroleptic Malignant Syndrome Induced by Antipsychotic Monotherapy Using Dantrolene. ( 30775657 )
2019
6
Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study. ( 30811377 )
2019
7
Neuroleptic malignant syndrome as part of an akinetic crisis associated with sepsis in a patient with Lewy body disease. ( 30824461 )
2019
8
An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome. ( 30858642 )
2019
9
A rare iatrogenic association of syndrome of inappropriate secretion of antidiuretic hormone, neuroleptic malignant syndrome and rhabdomyolysis. ( 30949348 )
2019
10
A Mixed Presentation of Serotonin Syndrome Versus Neuroleptic Malignant Syndrome in a 12-Year-Old Boy. ( 30964850 )
2019
11
Electroconvulsive Therapy for Neuroleptic Malignant Syndrome: A Case Series. ( 31022041 )
2019
12
Atypical neuroleptic malignant syndrome - A case report. ( 31071486 )
2019
13
Levosulpiride-induced neuroleptic malignant syndrome in rheumatoid arthritis. ( 30100569 )
2018
14
Toxic Myopathy due to Antidopaminergic Medication Without Neuroleptic Malignant Syndrome. ( 30439755 )
2018
15
Neuroleptic malignant syndrome as a presenting feature of subacute sclerosing panencephalitis. ( 29243130 )
2018
16
Neuroleptic Malignant Syndrome: Diagnosis and Management. ( 29325237 )
2018
17
Neuroleptic malignant syndrome in pregnancy: case report and literature review. ( 29363376 )
2018
18
Neuroleptic malignant syndrome: a case responding to electroconvulsive therapy plus bupropion. ( 29441189 )
2018
19
Case report of neuroleptic malignant syndrome with prolonged mental changes and severe dyskinesia. ( 29464897 )
2018
20
A Neuroleptic Malignant Syndrome Without Rigidity. ( 29475219 )
2018
21
Dantrolene for Treatment of Suspected Neuroleptic Malignant Syndrome. ( 29548378 )
2018
22
Serotonin syndrome versus neuroleptic malignant syndrome: a case report. ( 29616715 )
2018
23
Reversible splenial lesion in neuroleptic malignant syndrome. ( 29696960 )
2018
24
A Mixed Presentation of Serotonin Syndrome vs Neuroleptic Malignant Syndrome in a 12-Year-Old Boy. ( 29698346 )
2018
25
Olanzapine as a cause of neuroleptic malignant syndrome, bibliographic review following a clinical case. ( 29892970 )
2018
26
Diagnostic, Treatment, and System Challenges in the Management of Recurrent Neuroleptic Malignant Syndrome on a General Medical Service. ( 29992074 )
2018
27
Neuroleptic malignant syndrome following reintroduction of an antipsychotic after overdose. ( 30076161 )
2018
28
Neuroleptic Malignant Syndrome: The Value of Diagnostic Criteria. ( 30085440 )
2018
29
Forced Diuresis and Expedient Blood Pressure Control in the Management of Quetiapine Induced Neuroleptic Malignant Syndrome: A Case Report. ( 30087734 )
2018
30
A Case of Neuroleptic Malignant Syndrome in a Profoundly Intellectually Disabled Patient with Successful Reintroduction of Antipsychotic Therapy with Quetiapine. ( 30112240 )
2018
31
Atypical Neuroleptic Malignant Syndrome Precipitated by Clozapine and Quetiapine Overdose: A Diagnostic Challenge. ( 30254795 )
2018
32
Acute Abdomen with Ileus: A Heralding Presentation of Neuroleptic Malignant Syndrome. ( 30323731 )
2018
33
Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. ( 30375086 )
2018
34
Pharmacist-Initiated Management of a Suspected Case of Risperidone-Induced Neuroleptic Malignant Syndrome in an Aged-Care Resident. The Role of Residential Medication Management Reviews in Medication Safety. ( 30428759 )
2018
35
Neuroleptic malignant syndrome in a patient treated with clotiapine. ( 30439816 )
2018
36
Psoas Abscess as a Differential Diagnosis of Neuroleptic Malignant Syndrome in a Schizoaffective Disorder Patient With Catatonic Symptoms. ( 30444963 )
2018
37
Neuroleptic malignant syndrome and serotonin syndrome. ( 30459031 )
2018
38
Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015. ( 30506147 )
2018
39
Neuroleptic malignant syndrome in a young adult female at the university of Benin Teaching Hospital: a case report. ( 30603012 )
2018
40
Risperidone-Associated Neuroleptic Malignant Syndrome in an Inpatient With Schizophrenia, With Successful Rechallenge and 3 Year Follow-Up. ( 30618887 )
2018
41
Pulmonary embolism in a patient with neuroleptic malignant syndrome. ( 30631408 )
2018
42
Managing Manic Delirium in Bipolar Disorder With Features of Mania, Catatonia, and Neuroleptic Malignant Syndrome. ( 29272572 )
2017
43
Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Risk of Neuroleptic Malignant Syndrome. ( 27836566 )
2017
44
Clinically mild encephalopathy with a reversible splenial lesion and nonconvulsive status epilepticus in a schizophrenic patient with neuroleptic malignant syndrome. ( 27976828 )
2017
45
Confusing Terminology-Neuroleptic Malignant Syndrome vs Malignant Hyperthermia. ( 28558090 )
2017
46
Confusing Terminology-Neuroleptic Malignant Syndrome vs Malignant Hyperthermia-Reply. ( 28558105 )
2017
47
Progressive Encephalomyelitis with Rigidity and Myoclonus in an Intellectually Disabled Patient Mimicking Neuroleptic Malignant Syndrome. ( 28352055 )
2017
48
Neuroleptic malignant syndrome with thyroid disorder: An unusual case report. ( 28953679 )
2017
49
Neuroleptic malignant syndrome in a patient with stable dose of olanzapine. ( 29026773 )
2017
50
Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management. ( 29061403 )
2017

Variations for Neuroleptic Malignant Syndrome

Expression for Neuroleptic Malignant Syndrome

Search GEO for disease gene expression data for Neuroleptic Malignant Syndrome.

Pathways for Neuroleptic Malignant Syndrome

GO Terms for Neuroleptic Malignant Syndrome

Biological processes related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 release of sequestered calcium ion into cytosol GO:0051209 8.96 DRD2 RYR1
2 response to hypoxia GO:0001666 8.8 DRD2 MB RYR1

Molecular functions related to Neuroleptic Malignant Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 8.62 CYP2D6 DRD2

Sources for Neuroleptic Malignant Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....